- Home
- MDXG vs REAL Comparison
MDXG vs REAL Comparison
Compare MDXG & REAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MDXG | REAL |
|---|---|---|
| Founded | 2006 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Specialty Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.7B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | MDXG | REAL |
|---|---|---|
| Price | $7.08 | $16.24 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 8 |
| Target Price | $11.00 | ★ $15.29 |
| AVG Volume (30 Days) | 722.5K | ★ 2.5M |
| Earning Date | 10-29-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | $393,442,000.00 | ★ $662,789,000.00 |
| Revenue This Year | $19.13 | $17.10 |
| Revenue Next Year | $2.11 | $10.90 |
| P/E Ratio | $26.21 | ★ N/A |
| Revenue Growth | ★ 14.77 | 14.30 |
| 52 Week Low | $5.79 | $4.61 |
| 52 Week High | $9.71 | $16.33 |
Technical Indicators
Market Signals| Indicator | MDXG | REAL |
|---|---|---|
| Relative Strength Index (RSI) | 51.32 | 68.97 |
| Support Level | $6.91 | $15.13 |
| Resistance Level | $7.45 | $16.08 |
| Average True Range (ATR) | 0.24 | 0.78 |
| MACD | 0.01 | 0.10 |
| Stochastic Oscillator | 53.50 | 96.11 |
Price Performance
Historical ComparisonAbout MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
About REAL The RealReal Inc.
The RealReal is the largest pure-play luxury resale platform in the US, generating $1.8 billion in 2024 gross merchandise volume and addressing a niche (personal luxury resale) that had previously been serviced by inefficient upscale boutiques and local pawn shops. The company generates revenue via consignment and first-party sales on its online marketplace, and through a small volume of direct sales. With a hands-on approach that actively sources inventory and authenticates every item on its platform, The RealReal is able to justify much higher take rates than peers, working out to roughly 36% of net merchandise value in 2024, which excludes returns, cancellations, and first-party sales.